BI Asset Management Fondsmaeglerselskab A S Purchases Shares of 116,758 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

BI Asset Management Fondsmaeglerselskab A S bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 116,758 shares of the biopharmaceutical company’s stock, valued at approximately $2,437,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after buying an additional 390,116 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Renaissance Technologies LLC increased its stake in Catalyst Pharmaceuticals by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company’s stock worth $56,477,000 after purchasing an additional 180,100 shares in the last quarter. Boston Partners raised its holdings in Catalyst Pharmaceuticals by 1.3% during the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock worth $27,325,000 after buying an additional 16,601 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Catalyst Pharmaceuticals by 6.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock valued at $26,023,000 after buying an additional 79,182 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $22.02 on Tuesday. The company has a market capitalization of $2.69 billion, a P/E ratio of 18.66, a P/E/G ratio of 3.31 and a beta of 0.79. The stock’s 50 day moving average price is $22.59 and its 200 day moving average price is $22.13. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on CPRX. Bank of America restated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Stephens reissued an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird lifted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.